1921
Volume 102, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

In immunocompromised patients, visceral leishmaniasis (VL) can present with atypical clinical symptoms that include poor response to treatment. No optimal therapeutic regimen is available for such cases. In a splenectomized male patient, we observed a disseminated form of the disease in the liver, bone marrow, lymph nodes, and gastrointestinal tract. There was an apparent clinical improvement when he was initially treated with liposomal amphotericin B (L-AmB), but this was followed by a relapse involving severe clinical symptoms. He was finally treated successfully with a combination of L-AmB, meglumine antimoniate, and pentamidine isethionate. It is important to include asplenia as an immunosuppressive condition that induces exotic VL pathologies. In such cases, combination anti- drug therapy should be considered.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0999
2019-12-23
2021-01-18
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/2/tpmd180999.html?itemId=/content/journals/10.4269/ajtmh.18-0999&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2010. Control of the Leishmaniases. Report of a Meeting of the WHO Expert Committee on Control of Leishmaniases. WHO Technical Report Series No. 949. Geneva, Switzerland, March 22–26, 2010.
    [Google Scholar]
  2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M; WHO Leishmaniasis Control Team, 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.
    [Google Scholar]
  3. Lindoso JA, Cota GF, Cruz AMda, Goto H, Maia-Elkhoury ANS, Romero GAS, Sousa-Gomes MLde, Santos-Oliveira JR, Rabello A, 2014. Visceral leishmaniasis and HIV coinfection in Latin America. PLoS Negl Trop Dis 8: e3136.
    [Google Scholar]
  4. Saporito L, Giammanco GM, De Grazia S, Colomba C, 2013. Visceral leishmaniasis: host–parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host. Int J Infect Dis 17: e572e576.
    [Google Scholar]
  5. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-velez R, Weina P, Carvalho EM, Ephros M, 2018. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 63: e202e264.
    [Google Scholar]
  6. Ministério da Saúde do Brasil, 2011. Leishmaniose Visceral: Recomendações Clínicas para Redução da Letalidade, 1st edition. Brasília, Brazil: Editora do Ministério da Saúde, 1730.
    [Google Scholar]
  7. Olea P, 2013. Leishmaniosis visceral en un paciente con infección por VIH. Rev Chil Infectol 30: 216220.
    [Google Scholar]
  8. Agarwal P, Kumar V, Kaushal M, Kumari M, Chaudhary A, 2017. Indian visceral leishmaniasis with extensive lymphadenopathy–an unusual presentation: a case report with literature review. Cytojournal 14: 9.
    [Google Scholar]
  9. Eibl M, 1985. Immunological consequences of splenectomy. Prog Pediatr Surg 18: 139145.
    [Google Scholar]
  10. Siddig M, Ghalib H, Shillington DC, Petersen EA, Khidir S, 1990. Visceral leishmaniasis in Sudan. Clinical features. Trop Geogr Med 42: 107112.
    [Google Scholar]
  11. Pomares-Estran C, Cenderello G, Ittel A, Karsenti JM, Cardot-Leccia N, Vassalo M, Hasseine L, Delaunay P, Rosenthal E, Marty P, 2009. Isolated lymphadenopathy in Leishmania infantum infection: three case reports. Ann Trop Med Parasitol 103: 555559.
    [Google Scholar]
  12. Aleixo JA, Nascimento ET, Monteiro GR, Fernandes MZ, Ramos AMO, Wilson ME, Pearson RD, Jeronimo SMB, 2006. Atypical American visceral leishmaniasis caused by disseminated Leishmania amazonensis infection presenting with hepatitis and adenopathy. Trans R Soc Trop Med Hyg 100: 7982.
    [Google Scholar]
  13. Adamama-moraitou KK, Rallis TS, Koytinas AF, Tontis D, Plevraki K, Kritsepi M, 2007. Asymptomatic colitis in naturally infected dogs with Leishmania infantum: a prospective study. Am J Trop Med Hyg 76: 5357.
    [Google Scholar]
  14. Idoate MA, Vazquez JJ, Civeira P, 1993. Rectal biopsy as a diagnostic procedure of chronic visceral leishmaniasis. Histopathology 22: 589590.
    [Google Scholar]
  15. Napier LE, 1949. Splenectomy in the treatment of kala-azar. J Trop Med Hyg 52: 243248.
    [Google Scholar]
  16. Dutra RA, Dutra LF, Reis Mde O, Lambert RC, 2012. Splenectomy in a patient with treatment-resistant visceral leishmaniasis: a case report. Rev Soc Bras Med Trop 45: 130131.
    [Google Scholar]
  17. Kumar R, Daga MK, Kamble NL, Sothwal A, Singh T, Nayak HK, Raizada N, 2011. Rare association of visceral leishmaniasis with Hodgkin’s disease: a case report. Infect Agent Cancer 6: 17.
    [Google Scholar]
  18. Osakwe NM, Paulus A, Haggerty PF, Wood RA, Becker SJ, Weina PJ, Dolan MJ, Prakash V, 2013. Visceral leishmaniasis with associated immune dysregulation leading to lymphoma. Mil Med 178: e386e389.
    [Google Scholar]
  19. Cartwright GE, Chung H-L, Chang A, 1948. Studies on the pancytopenia of kala-azar. Blood 3: 249275.
    [Google Scholar]
  20. Varma N, Naseem S, 2010. Hematologic changes in visceral leishmaniasis/kala azar. Indian J Hematol Blood Transfus 26: 7882.
    [Google Scholar]
  21. Magill AJ, 2015. Leishmania species: visceral (kala-azar), cutaneous, and mucosal leishmaniasis. Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th edition. Philadelphia, PA: Elsevier Saunders, 3097.
    [Google Scholar]
  22. McBride JA, Dacie JV, Shapley R, 1968. The effect of splenectomy on the leucocyte count. Br J Haematol 14: 225231.
    [Google Scholar]
  23. Chapman LAC, Dyson L, Courtenay O, Chowdhury R, Bern C, Medley GF, Hollingsworth TD, 2015. Quantification of the natural history of visceral leishmaniasis and consequences for control. Parasit Vectors 8: 521.
    [Google Scholar]
  24. Belo VS, Struchiner CJ, Barbosa DS, Nascimento BWL, Horta MAP, da Silva ES, Werneck GL, 2014. Risk factors for adverse prognosis and death in American visceral leishmaniasis: a meta-analysis. PLoS Negl Trop Dis 8: e2982.
    [Google Scholar]
  25. Gonzáilez JL, Insa F, Novoa C, Pizarro M, 1986. Intestinal amyloidosis in hamsters with visceral leishmaniasis. Br J Exp Path 67:353360.
    [Google Scholar]
  26. Chattopadhyay A, Jafurulla M, 2011. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis. Biochem Biophys Res Commun 416: 712.
    [Google Scholar]
  27. Croft SL, 2018. Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD. Parasitology 145: 237247.
    [Google Scholar]
  28. Croft S, Yardley V, 2002. Chemotherapy of leishmaniasis. Curr Pharm Des 8: 319342.
    [Google Scholar]
  29. Van Griensven J, Carrillo E, López-Vélez R, Lynen L, Moreno J, 2014. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 20: 286299.
    [Google Scholar]
  30. Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M, 2009. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 48: e16e22.
    [Google Scholar]
  31. Maia C, Nunes M, Marques M, Henriques S, Rolão N, Campino L, 2013. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs. Exp Parasitol 135: 3641.
    [Google Scholar]
  32. Gomes MAF, Medeiros LLC, Lobo FPD, Wanderley NRS, Matos APR, Jácome TDN, Monteiro MGL, Luz KG, 2018. Combination therapy with liposomal amphotericin b (Ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case. Rev Soc Bras Med Trop 51: 393396.
    [Google Scholar]
  33. Assis TSM, Rosa DCP, Teixeira EM, Cota G, Azeredo-da-Silva ALF, Werneck G, Rabello A, 2017. The direct costs of treating human visceral leishmaniasis in Brazil. Rev da Soc Bras Med Trop 50: 478482.
    [Google Scholar]
  34. Morizot G et al., 2016. Antimony to cure visceral leishmaniasis unresponsive to liposomal amphotericin B. PLoS Negl Trop Dis 10: e0004304.
    [Google Scholar]
  35. Cota GF, de Sousa MR, Fereguetti TO, Rabello A, 2013. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis 7: e2195.
    [Google Scholar]
  36. Ministério da Saúde do Brasil, 2006. Tratamento. Manual de Vigilância e Controle da Leishmaniose Visceral, 1st edition. Brasília, Brazil: Editora do Ministério da Saúde, 3140.
    [Google Scholar]
  37. Woods ML, 2018. Pentamidine. Grayson ML, Cosgrove SE, Crowe SM, Hope W, Mccarthy JS, Mills J, Mouton JW, Paterson DL, eds. Kucers’ the Use of Antibiotics : A Clinical Review of Antibacterial, Antifungal, Antiparasitic and Antiviral Drugs, 7th edition. Boca Raton, FL: CRC Press, 33243331.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0999
Loading
/content/journals/10.4269/ajtmh.18-0999
Loading

Data & Media loading...

  • Received : 21 Dec 2018
  • Accepted : 14 Jul 2019
  • Published online : 23 Dec 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error